Abstracts tagged "Pulmonary complications and systemic vasculitides"

Abstract Number: 1932 • 2016 ACR/ARHP Annual Meeting
Precapillary Pulmonary Hypertension in Granulomatosis with Polyangiitis: A Case Series with Long-Term Follow-up
Xavier Puéchal¹, Xavier Jaïs², Claire Le Hello³, Anne Grasland⁴, Assia Eslami¹, Jesús Rolando de la Jara Cordero¹, Benjamin Terrier^1,5, David Launay⁶, Loïc Guillevin¹, Marc Humbert² and Luc Mouthon for the French Vasculitis Study Group¹, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ²Le Kremlin–Bicêtre University Hospital, Bicêtre, France, ³Caen University Hospital, caen, France, ⁴Béclère University Hospital, Clamart, France, ⁵Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁶Lille University Hospital, Lille, France
Background/Purpose: A few isolated case reports of precapillary pulmonary hypertension (PH) in ANCA-associated vasculitides, mostly granulomatosis with polyangiitis (GPA), have been published. The characteristics and…
Abstract Number: 880 • 2015 ACR/ARHP Annual Meeting
Extra-Corporeal Membrane Oxygenation and Diffuse Alveolar Haemorrhage: A Single Centre Case Series and Analysis of the ELSO Database
Chai Yiing Ling¹, Thomas Simpson², Guy Glover², Chris Meadows³, Nicholas Ioannou³, Boris Lams³ and David P. D'Cruz⁴, ¹Louise Coote Lupus Unit, Guy's & St Thomas' Hospital, London, United Kingdom, ²Critical Care, Kings Health Partners, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom, ³Kings Health Partners, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom, ⁴Louise Coote Lupus Unit, Guy's and St Thomas' Hospital, London, United Kingdom
Background/Purpose: Diffuse alveolar haemorrhage (DAH) is a rare and potentially fatal complication of the systemic vasculitides and may present directly to the intensivist as a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].